Admedus Corp.

8400 Normandale Lake Blvd Suite 920
Minneapolis, MN 55437 USA
Click for website

Research Sector Tissue Impants

Summary Description A new generation of tissue bio-implants that more easily integrate into recipient tissue, show less capacity for rejection and have the potential to replace many of the products that surgeons currently use.

Management Julian Chick, Chief Operating Officer; Stephen Mann, Chief Financial Officer and Company Secretary; Lynne Bradshaw, Director-Marketing; Danny Zanardo, Director-Sales; Helen Wray, VP of Operations

Click here for Financial Data
Keywords: Regenerative Tissue, Bio-Implants, Rejection, Surgery, Heart


Updated: Mar. 18, 2016


Admedus Corp. is the American arm of Australian ASX-listed Admedus Ltd a diversified healthcare company focused on developing and commericalizing technologies with global potential. Working with ......view more

Products / Services

CardioCel - A solution for life. CardioCel is currently undergoing regulatory approval in the US but is now available for sale in Europe. CardioCel is a new type of cardiovascular scaffold that......view more

Technology / Differentiation

Our patented ADAPT tissue engineering process has enabled our scientific team to create a biological scaffold that more readily promotes native tissue in-growth. Tissue bio-implants developed usin...view more

Market / Customers

Cardiovascular Surgery......view more